Phio Pharmaceuticals has signed an agreement with a U.S.-based manufacturer to produce its lead compound PH-762 for upcoming clinical trials and commercial supply. PH-762, an siRNA therapy targeting skin cancers, has shown promising safety and efficacy in Phase 1b trials with a 65% pathological response rate. The company plans to engage the FDA in Q2 2026 for next-stage clinical development and expects its current cash reserves to fund operations into mid-2027. This partnership aims to leverage U.S. manufacturing expertise to support Phio's cancer treatment advancements.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
